21019-30-7
Chemical Structure
Methyllycaconitine
Synonym(s): MLA
- CAS No.: 21019-30-7
- Formula:C37H50N2O10
- Molecular Weight:682.80
IUPAC Name: ((3S,6S,7R,7aR,8S,9R,10S,11aR,13S,14R)-1-ethyl-11a,12-dihydroxy-6,8,10,13-tetramethoxydodecahydro-2H-3,6a,12-(epiethane[1,1,2]triyl)-7,9-methanonaphtho[2,3-b]azocin-3(4H)-yl)methyl 2-((S)-3-methyl-2,5-dioxopyrrolidin-1-yl)benzoate
InChIKey: XLTANAWLDBYGFU-VTLKBQQISA-N
SMILES: CO[C@@H]1[C@@]23[C@@]4([H])[C@](CN([C@]2([H])[C@]([C@H]4OC)([C@@]5([C@]6([H])[C@@]3([H])C[C@@]([C@H](C5)OC)([H])[C@@H]6OC)O)O)CC)(CC1)COC(C7=C(N8C(C[C@@H](C8=O)C)=O)C=CC=C7)=O
Biological Activity: Methyllycaconitine (MLA) is a blood-brain barrier-permeable antagonist of α7 nicotinic acetylcholine receptor (α7nAChR) with an IC50 of 2 nM. Methyllycaconitine inhibits Aβ25-35-induced autophagy by restoring the mTOR pathway, and prevents reactive oxygen species (ROS) production, microglial activation, reduced dopamine uptake, loss of dopaminergic terminals and catecholamine secretion. Methyllycaconitine induces hippocampal glutamate efflux, enhances long-term potentiation, and improves memory acquisition. Methyllycaconitine can be used in research related to Alzheimer's disease, cerebral palsy, Parkinson's disease and schizophrenia[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Methyllycaconitine | Methyllycaconitine (MLA) is a blood-brain barrier-permeable antagonist of α7 nicotinic acetylcholine receptor (α7nAChR) with an IC50 of 2 nM. Methyllycaconitine inhibits Aβ25-35-induced autophagy by restoring the mTOR pathway, and prevents reactive oxygen species (ROS) production, microglial activation, reduced dopamine uptake, loss of dopaminergic terminals and catecholamine secretion. Methyllycaconitine induces hippocampal glutamate efflux, enhances long-term potentiation, and improves memory acquisition. Methyllycaconitine can be used in research related to Alzheimer's disease, cerebral palsy, Parkinson's disease and schizophrenia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Zheng X, et al. Methyllycaconitine alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. PloS one. 2014;9(10):e111536. [Content Brief]
- [2]. Escubedo E, et al. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: involvement of alpha7 nicotinic receptors. The Journal of pharmacology and experimental therapeutics. 2005 Nov;315(2):658-67. [Content Brief]
- [3]. Qasem AMA, et al. Synthesis and Antagonist Activity of Methyllycaconitine Analogues on Human α7 Nicotinic Acetylcholine Receptors. ACS bio & med chem Au. 2023 Apr 19;3(2):147-157. [Content Brief]
- [4]. van Goethem NP, et al. Antagonizing α7 nicotinic receptors with methyllycaconitine (MLA) potentiates receptor activity and memory acquisition. Cellular signalling. 2019 Oct;62:109338. [Content Brief]
Keywords
